April 26, 2021

Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes

NEJM

https://pubmed.ncbi.nlm.nih.gov/?myncbishare=dukemlib&dr=abstract&otool=dukemlib&term=33789013

Bottom line- patients with dm and established heart disease should take the medication with proven cardiovascular benefits such as a GLP-1 receptor agonist or an SGLT2 inhibitor. In pts with dm and heart failure with reduced EF or with chronic CKD, SGLT2 inhibitors with proven benefit should be considered.  If weight loss is a consideration the GLP-1 receptor agonist class is more helpful.